EQS Group-Media / 2020-06-03 / 19:30
*Media release *
*Medacta Receives CE Marking for its Long Diaphysis and Stemless Metaphysis
Implants for Shoulder Joint Replacement*
_CASTEL SAN PIETRO_, _03 June 2020 _- Medacta today announced it has
obtained CE marking for its Long Humeral Diaphysis and Stemless Humeral
Metaphysis implants for shoulder joint replacement.
*Long Humeral Diaphysis and Stemless Metaphysis: More Options in Shoulder
Arthroplasty*
The Long Humeral Diaphysis, which has recently obtained clearance from the
Food and Drug Administrations (FDA) for use in the U.S., can help surgeons
facing complex cases of shoulder replacement, particularly when there is a
need for extended distal fixation.
The Stemless Humeral Metaphysis is intended for use in anatomic
configuration and enables a minimally invasive approach at the humeral
level, preserving the humeral canal. The Stemless Humeral Metaphysis
features Medacta's 3D Metal surface, an advanced, 3D-printed structure
designed to improve the metal-bone mechanical bond.
Medacta collaborated with several expert surgeons to develop its new options
for shoulder replacement. Prof. Dr. Bernhard Jost, Chief of Department /
Head Shoulder-Elbow, Department of Orthopaedics and Traumatology,
Kantonsspital St. Gallen, Switzerland, is one of the designers and has
worked closely with Medacta's engineers on the successful development of
both the Long Humeral Diaphysis and Stemless Humeral Metaphysis.
"With these two additional components, the Medacta Shoulder System becomes
more complete, allowing surgeons to widen their clinical use of the system
by addressing more patient morphologies and pathologies," said Prof. Jost.
Francesco Siccardi, CEO of Medacta has stated: "Since its founding in 1999,
Medacta has focused on developing new and improved products, technologies
and methodologies for the orthopaedics market. In the intervening 20 years,
Medacta has become a pioneer in developing new offerings based on minimally
invasive surgical techniques that help support faster recovery and an
improved patient experience. With the new Stemless Humeral Metaphysis,
Medacta is now able to offer a minimally invasive solution for shoulder
arthroplasty and continue our commitment to improve the care and well-being
of orthopaedic patients around the world".
*Responsible Introduction to the Market for a Complete and Innovative
Shoulder Portfolio *
The Long Humeral Diaphysis and Stemless Metaphysis will be introduced in
select hospitals following the guidelines of Medacta's M.O.R.E. Excellence
Clinical Program. With the goal of responsibly introducing innovative
products to the market, Medacta releases new products on a restricted basis
to conduct voluntary clinical programs in order to further document and
confirm their efficacy.
Both implants are part of the Medacta Shoulder System, an innovative
shoulder replacement system that features a broad range of options and
allows surgeons to choose the best implant for their patients. As a modular
system, the Medacta Shoulder System offers the flexibility to move, if
necessary, from a hemi-arthroplasty to a total or reverse arthroplasty.
Since the implants are compatible and work in conjunction with each other,
this innovative system is complete and convertible. With these new implants,
the Medacta Shoulder System becomes even more robust with a comprehensive
range of stemless, short, standard and long stems.
To learn more about Medacta's shoulder portfolio, please visit
shoulder.medacta.com [1].
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specialized in the design and production
of innovative orthopaedic products and the development of accompanying
surgical techniques for joint replacement, spine surgery, and sports
medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "MySolutions" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Research/Technology
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1061977
End of News EQS Group Media
1061977 2020-06-03
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1321e0aebb484f68b82d52d43490bca2&application_id=1061977&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 03, 2020 13:30 ET (17:30 GMT)
